XBiotech (4XB) AI Stock Analysis

XBiotech

(BX Swiss:4XB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Negative Factors

XBiotech (4XB) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 57.32M
Dividend Yield: ―
Average Volume (3M): 67
Price to Earnings (P/E): -1.3
Beta (1Y): -0.18
Revenue Growth: ―
EPS Growth: -60.25%
Country: Switzerland
Employees: 87
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

XBiotech Business Overview & Revenue Model

Company Description

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inf...

XBiotech Risk Analysis

XBiotech disclosed 39 risk factors in its most recent earnings report. XBiotech reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.24 PART II - OTHER INFORMATION Item 1. Risk Factors There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2025. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.Q2, 2026

XBiotech Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:4XB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACET	46Neutral	$32.02M	-0.30	-74.90%	―	―	44.73%
ATRA	46Neutral	$80.40M	-6.79	44.67%	―	-96.72%	-253.97%
XLO	44Neutral	$52.84M	-5.39	-50.77%	―	327.25%	85.65%
ELTX	40Underperform	$45.51M	-0.79	-1266.43%	―	―	49.43%
TCRX	39Underperform	$11.83M	-0.19	-108.72%	―	2.15%	17.34%

* Healthcare Sector Average

Performance Comparison

CH:4XB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:4XB	XBiotech Inc.	1.79	0.00	0.00%
ATRA	Atara Biotherapeutics Inc	8.01	-5.84	-42.17%
ACET	Adicet Bio Inc	3.42	-8.26	-70.72%
ELTX	Elicio Therapeutics, Inc	1.68	-7.57	-81.84%
TCRX	Tscan Therapeutics, Inc.	0.17	-1.07	-85.97%
XLO	Xilio Therapeutics Inc	8.03	-3.87	-32.51%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

XBiotech AI Stock Analysis